Hypocalcemia

Etiology

The causes of hypocalcemia can be broadly classified into 3 broad categories: PTH deficiency, hypocalcemia with elevated PTH, and other causes. This classification reflects the underlying pathophysiologic mechanisms that impair calcium regulation.

Parathyroid Hormone Deficiency 

Decreased PTH levels (low or inappropriately normal serum PTH) may result from destruction of the parathyroid glands (postsurgical or autoimmune), abnormal regulation of PTH production and secretion, or abnormal parathyroid gland development. Postsurgical injury or removal of the parathyroid gland is the most common cause of hypoparathyroidism. Hypocalcemia due to low PTH is confirmed by 2 separate measurements of low calcium at least 2 weeks apart in the presence of inappropriately low PTH levels.[5]

Postsurgical hypoparathyroidism is the most common cause of hypoparathyroidism, accounting for approximately 75% of cases, and typically occurs after thyroidectomy, parathyroidectomy, or radical neck surgery.[2][6][7] Most patients undergoing parathyroidectomy recover parathyroid function within 1 month (about 70%-80%). In patients with severe hyperparathyroidism, such as tertiary hyperparathyroidism associated with CKD, the abrupt postoperative decline in PTH can lead to severe hypocalcemia due to unopposed osteoblastic activity, causing rapid skeletal calcium uptake, a condition known as hungry bone syndrome.[8][9][10] 

Hungry bone syndrome is characterized by marked hypocalcemia and may also be associated with hypophosphatemia and hypomagnesemia.[11] Scases require aggressive intravenous calcium replacement and close monitoring, particularly in patients with prolonged preoperative hyperparathyroidism.[12] Emerging interventions, such as intraoperative ischemic preconditioning of the parathyroid glands during thyroidectomy, may accelerate recovery of parathyroid function and reduce the duration of postoperative hypocalcemia.[13]

Autoimmune hypoparathyroidism results from autoantibodies against the parathyroid gland and represents the leading cause of autoimmune-mediated hyperparathyroidism. A common hereditary form occurs in autoimmune polyglandular syndrome type I, which is characterized by the triad of hypoparathyroidism, chronic mucocutaneous candidiasis, and adrenal insufficiency. This syndrome is also called autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APECED).[14]

Abnormal parathyroid gland development can lead to hypoparathyroidism and may occur as an isolated defect or associated with complex congenital syndromes. Several genetic disorders are associated with this condition, including DiGeorge syndrome, CHARGE syndrome, Gracile bone dysplasia, mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), and Medium-chain acyl-CoA dehydrogenase deficiency.[5]

Parathyroid gland destruction may occur from several rare causes, including infiltrative disorders such as granulomatous diseases, hemochromatosis, Wilson disease, and amyloidosis, as well as from aluminum-containing phosphate binders and irradiation. HIV infection is rarely associated with immune cell infiltration of the parathyroid gland. Certain chemotherapeutic agents, including nivolumab and L-asparaginase, have also been reported to cause parathyroid gland destruction.[2] 

High Parathyroid Hormone Levels

In absolute or relative vitamin D deficiency, vitamin D maintains normal serum calcium levels by enhancing intestinal calcium absorption and facilitating bone resorption. Vitamin D deficiency may result from decreased intake or malabsorption, limited sun exposure (more common in individuals with darker skin), liver disease, kidney disease, or impaired conversion to its active metabolite (1,25-dihydroxyvitamin D). Active 1,25-dihydroxyvitamin D (calcitriol) is the principal regulator of intestinal calcium absorption.[15] 

Vitamin D deficiency–related hypocalcemia leads to compensatory increase in PTH secretion, resulting in secondary hyperparathyroidism. Low Vitamin D levels before neck surgery are also associated with an increased risk of postoperative hypocalcemia and hypoparathyroidism.[16][17] 

CKD impairs phosphate excretion and hydroxylation of 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D. These changes stimulate increased PTH secretion and lead to secondary hyperparathyroidism. However, impaired vitamin D metabolism and persistent hyperphosphatemia limit calcium absorption, so serum calcium levels remain low despite elevated PTH.

Pseudohypoparathyroidism is a genetic disorder characterized by end-organ resistance to the action of PTH. This condition typically presents with hypocalcemia, hyperphosphatemia, and elevated PTH levels despite normal or increased hormone production.[5]

Pharmacological Causes

Drugs can contribute to hypocalcemia through multiple mechanisms. Bisphosphonates and denosumab inhibit osteoclastic bone resorption and may lower serum calcium.[18] Recent data demonstrate that 21.1% of patients with osteoporosis developed hypocalcemia following denosumab therapy, with diuretic use and vitamin D deficiency identified as significant risk factors.[19] Pharmacovigilance data from the Food and Drug Administration Adverse Event Reporting System further identify hypocalcemia as one of the most frequently reported adverse events associated with 120 mg denosumab in oncology practice, occurring in 7.29% of reported cases.[20] 

Cinacalcet reduces PTH secretion by activating the CaSR and can also cause hypocalcemia. Cisplatin, a chemotherapeutic drug, can also induce hypocalcemia through hypomagnesemia, whereas foscarnet can cause hypocalcemia by forming complexes with ionized calcium, thereby reducing physiologically active calcium.

Concomitant vitamin D deficiency increases the risk of hypocalcemia in patients receiving these drugs; vitamin D and calcium levels should be corrected before initiating these treatments. Regular monitoring of calcium levels, including ionized calcium, is recommended during treatment, particularly with agents such as foscarnet.[21][22]

Other Causes

In addition to disorders of PTH and vitamin D metabolism, hypocalcemia may arise from a variety of other etiologies that disrupt calcium balance, including medication effects, electrolyte abnormalities, acute illness, and systemic conditions.

• Pseudohypocalcemia is characterized by a falsely low total serum calcium level due to reduced protein binding, most commonly in hypoalbuminemia. Ionized calcium levels remain normal; therefore, total serum calcium should be corrected by adding approximately 0.8 mg/dL for each 1 g/dL decrease in serum albumin below 4 gm/dL.

• Acid-base disturbances affect calcium binding to albumin in a pH-dependent manner. Ionized calcium increases in acidosis due to reduced albumin binding and decreases in alkalosis due to enhanced binding. As no reliable correction factor exists, direct measurement of ionized calcium is recommended.

• Acute pancreatitis is commonly associated with hypocalcemia due to saponification, in which calcium binds to free fatty acids released during pancreatic autodigestion of mesenteric fat, resulting in calcium precipitation. Hypocalcemia is included in the Ranson criteria and is associated with a poorer prognosis.[23][24]

• Severe sepsis, critical illness, and trauma are commonly associated with hypocalcemia through various mechanisms, including impaired PTH secretion, magnesium dysregulation, catecholamine-mediated intracellular calcium shifts, and reduced calcitriol production.[24][25] Hypocalcemia has also been reported in severe COVID-19 infection.[26][27] In trauma and shock, hypocalcemia frequently occurs following blood transfusions, as citrate binds circulating calcium and reduces ionized calcium levels.[26][28][29]

• Hypomagnesemia and hypermagnesemia can both contribute to hypocalcemia. Low serum magnesium induces PTH resistance and, in some severe cases (typically <0.8 mEq/L [1 mg/dL or 0.4 mmol/L]), impairs PTH secretion.[30][31] Conversely, severe hypermagnesemia, often in the setting of renal impairment, suppresses PTH release by reducing the sensitivity of CaSRs, leading to hypocalcemia.[32]

• Acute hyperphosphatemia is an uncommon cause of hypocalcemia resulting from extravascular deposition of calcium-phosphate products. This condition typically occurs when the calcium-phosphate product exceeds 60 mg²/dL².[33]

• Massive blood transfusion can cause an acute decline in ionized calcium because citrate, an anticoagulant used in stored blood, binds circulating calcium.[28][29]

• Pregnancy is associated with reported cases of hypocalcemia, most commonly related to poor dietary intake, hyperemesis gravidarum, or underlying medical diseases.[34]

• Neonatal hypocalcemia present within the first 72 hours of life is observed in preterm infants, in those with perinatal asphyxia due to increased calcitonin levels, and in infants born to mothers with diabetes mellitus or hyperparathyroidism.[35][36]

• Osteoblastic metastasis can cause hypocalcemia through increased skeletal calcium uptake driven by enhanced osteoblastic activity, similar to hungry bone syndrome. This phenomenon is most commonly observed in metastatic cancers, such as prostate cancer.[37]

Epidemiology

The literature lacks comprehensive data regarding the incidence and prevalence of hypocalcemia in the general population. The reported prevalence of transient hypocalcemia after thyroidectomy ranges from 6.9% to 49%, whereas permanent hypocalcemia occurs in approximately 0.4% to 33% of cases.[21] A 10-year retrospective analysis of benign thyroid surgery in Germany confirms that hypocalcemia remains a common postoperative complication, with variability across institutions.[38]

The most common causes of hypocalcemia include postsurgical states, CKD, vitamin D deficiency, magnesium deficiency, and acute pancreatitis. Smoking has been reported to decrease PTH and increase calcitonin levels; however, its overall effect on serum calcium levels remains unclear.[1]

Pathophysiology

Calcium is essential for numerous physiologic processes, including cellular function, nerve transmission, skeletal integrity, intracellular signaling, and blood coagulation. Neuronal and cardiac tissues are particularly sensitive to fluctuations in calcium levels. Intestinal calcium absorption is typically balanced by renal excretion, maintaining overall homeostasis. Serum calcium is tightly regulated by PTH, vitamin D, calcitonin, and FGF23.

PTH increases serum calcium by stimulating osteoclastic bone resorption and enhancing distal tubular reabsorption of calcium. PTH also promotes renal phosphate excretion and stimulates the conversion of 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D. Activated vitamin D increases intestinal absorption of calcium, enhances renal absorption, and facilitates bone reabsorption.

Calcitonin lowers serum calcium levels by inhibiting osteoclastic bone resorption. FGF23 inhibits the conversion of vitamin D to its active form, 1,25-dihydroxy vitamin D, thus reducing intestinal calcium absorption.

Acid-base disturbances alter calcium binding to albumin and influence the exchange of calcium and hydrogen ions between the intracellular and extracellular spaces. Acidosis reduces calcium binding to albumin, increasing ionized calcium levels, whereas alkalosis has the opposite effect. In addition, acidosis promotes the shift of calcium into the extracellular space in exchange for hydrogen ions, further increasing ionized calcium, whereas alkalosis favors the reverse.

History and Physical

The clinical manifestations of hypocalcemia range from asymptomatic in mild deficiency to life-threatening complications such as seizures, heart failure, or laryngospasm in severe cases. Presentation also depends on the rate of onset and chronicity of hypocalcemia. Evaluation should include a focused history and physical examination, as well as assessment for provoked signs. Common symptoms and signs of hypocalcemia include the following:[39][40]

• Seizures: Typically present in severe hypocalcemia and may present as an isolated manifestation or as part of a broader clinical syndrome.
• Tetany: Typically occurs with a rapid decline in serum ionized calcium and is often more severe; it is more commonly observed in respiratory alkalosis, which lowers ionized calcium levels.
• Paresthesias: May be perioral or involve the distal extremities.
• Psychiatric manifestations: Anxiety, depression, or emotional lability may occur but are less common.
• Carpopedal spasm (Trousseau sign): Reflects increased neuromuscular excitability; manifests as a hand spasm, with flexion of the thumb, wrist, and metacarpophalangeal joints and extension of the fingers when a sphygmomanometer is inflated above systolic blood pressure for 2 to 3 minutes.
• Chvostek sign: Another manifestation of increased neuromuscular excitability, elicited by tapping over the facial nerve anterior to the ear, resulting in ipsilateral contraction of facial muscles.
• QTc prolongation: A cardiac manifestation that may predispose to torsades de pointes, a potentially fatal ventricular tachyarrhythmia.
• Skin: Chronic hypocalcemia may cause dry skin, thin hair, and brittle nails.

The second component of the history and physical examination should focus on identifying the underlying etiology of hypocalcemia, including recent head and neck surgery, family history, gastrointestinal or kidney disease, and alcohol use that may contribute to hypomagnesemia.

Evaluation

The workup of hypocalcemia can be approached in a stepwise manner:

• Confirmation of hypocalcemia: The initial assessment should confirm hypocalcemia by correcting total serum calcium for albumin or by directly measuring ionized calcium. For every 1 g/dL decrease in serum albumin below 4 g/dL, approximately 0.8 mg/dL should be added to the total serum calcium level.

• Assessment of cardiac stability: An electrocardiogram should be obtained to evaluate for QTc prolongation, which increases the risk of torsades de pointes and may warrant treatment with intravenous magnesium.[40]

• Determining the etiology of hypocalcemia: Once confirmed, further evaluation should identify the underlying cause. This evaluation includes measurements of serum magnesium, phosphorus, intact PTH, and vitamin D levels. Certain etiologies may be evident from the clinical context, such as recent thyroid or parathyroid surgery, whereas the history and physical examination may guide additional tests (eg, serum lipase in suspected pancreatitis).

• Imaging of the skeletal system: Appropriate studies may reveal osteomalacia, rickets, or metastatic disease.

Treatment / Management

Treatment of hypocalcemia depends on symptom severity, the degree of calcium deficiency, and its underlying etiology. Prompt recognition and appropriate stratification are essential to prevent complications and guide targeted therapy.

Intravenous Calcium

Intravenous calcium is indicated in patients with severe symptoms, prolonged QTC intervals, or acute symptomatic hypocalcemia. Calcium gluconate 1 to 2 g (90 to 180 mg elemental calcium) or calcium chloride 1 g (270 mg elemental calcium) can be administered over 10 to 20 minutes, followed by continuous infusion if hypocalcemia persists.

Calcium gluconate is generally preferred due to a lower risk of tissue necrosis with extravasation. Alkaline solutions, such as bicarbonate and phosphorus-containing solutions, should not be administered through the same intravenous line to avoid precipitation of calcium salts.

Oral Calcium 

In patients with mild symptoms, oral calcium supplementation is appropriate. Calcium carbonate (40% elemental calcium) and calcium citrate (21% elemental calcium) are the most commonly used preparations. The typical goal is 1500 to 2000 mg of elemental calcium daily, divided into 2 to 3 doses to enhance absorption and minimize gastrointestinal and renal losses.

Calcium carbonate requires an acidic medium for optimal absorption and should be avoided in patients taking proton pump inhibitors. Vitamin D supplementation is often recommended to improve calcium absorption, particularly given the frequent coexistence of vitamin D deficiency. Calcitriol is typically prescribed in conjunction with calcium, with doses ranging from 0.25 mcg daily to 1 mcg twice daily. Serum calcium levels should be monitored closely to ensure adequate correction and avoid overtreatment.

Recombinant Human Parathyroid Hormone

Recombinant human PTH has been approved for the treatment of chronic hypoparathyroidism and certain genetic diseases associated with low PTH levels; however, its use has been limited due to manufacturing issues and restricted availability, which requires enrollment in a specialized program. Concerns have also been raised regarding potential long-term adverse effects, including bone pain and iatrogenic hyperparathyroidism.[41] 

A novel PTH analog, palopegteriparatide, was approved by the US Food and Drug Administration in 2024 for treating chronic hypocalcemia due to hypoparathyroidism.[7][42][43] Clinical data suggest improvements in renal function and quality of life in most patients with long-standing disease.[44][45][46] Palopegteriparatide should be considered in patients with inadequate calcium control on conventional therapy, persistent symptoms, or excessive treatment burden.[47](B3)

Palopegteriparatide is administered as a once-daily subcutaneous injection, with a starting dose of 18 mcg titrated based on serum calcium response. Calcium levels should be monitored every 7 to 10 days during dose titration and every 4 to 6 weeks once maintenance is achieved. The maximum recommended dose is 30 mcg daily.

Disease-Specific Treatment               

• Postsurgical hypoparathyroidism: Hypocalcemia commonly occurs after thyroidectomy or parathyroidectomy due to transient hypoparathyroidism. Prophylactic calcium supplementation is often recommended to reduce the risk of symptomatic hypocalcemia.[48] Serum calcium levels should be closely monitored postoperatively, and supplementation should be tapered as levels stabilize. 
(A1)

• Hypomagnesemia: Serum magnesium should be corrected before treating hypocalcemia.

• Vitamin D deficiency: Hypocalcemia due to vitamin D deficiency cannot be corrected without adequate vitamin D repletion.[49]

• CKD: Hypocalcemia in CKD is commonly due to impaired vitamin D metabolism and is typically treated with activated vitamin D (calcitriol). Patients with significant vitamin D deficiency may require ergocalciferol 50,000 units weekly for 8 to 12 weeks, followed by cholecalciferol 1000 to 5000 units daily. Patients with a history of nephrolithiasis should be counseled on risk-reduction strategies, including increased fluid intake and reduced dietary sodium and animal protein. 

Differential Diagnosis

The differential diagnosis of hypocalcemia includes hypoalbuminemia, acute pancreatitis or sepsis, acute kidney injury, hyperphosphatemia, hypomagnesemia, and disorders of parathyroid function. These conditions are often interrelated, making it challenging to distinguish the primary cause from secondary metabolic effects.

Prognosis

The overall prognosis of hypocalcemia is generally favorable, as it is often readily correctable. In rare cases, such as after complete parathyroidectomy, patients may require high doses of calcium and vitamin D to maintain normocalcemia. Similarly, patients with malabsorption following gastric bypass surgery may need substantial supplementation. Prolonged high-dose vitamin D therapy is associated with an increased risk of nephrolithiasis and nephrocalcinosis.

Complications

Patients with severe hypocalcemia (serum calcium <7 mg/dL) or an acute decline in calcium levels may develop seizures or life-threatening arrhythmias. Prompt electrocardiographic evaluation and aggressive correction of calcium are essential in these settings. Patients with poorly controlled hypoparathyroidism are at increased risk of renal complications, including nephrolithiasis and CKD, as well as reduced quality of life.[50][51]